Side-by-side comparison of the two widely studied GRPR radiotracers, radiolabeled NeoB and RM2, in a preclinical setting

CONCLUSION: Based on these findings, we conclude that the in vivo tumor-targeting capability of radiolabeled NeoB and RM2 is similar. Additional studies are needed to determine whether the differences observed in physiological organ uptakes, i.e., the pancreas, kidneys, and blood, result in relevant differences in organ absorbed doses when the radiotracers are applied for therapeutic purposes.PMID:37584725 | DOI:10.1007/s00259-023-06364-4

Source: Molecular Medicine - August 16, 2023 Category: Molecular Biology Authors: T S T Damiana P Para ïso C de Ridder D Stuurman Y Seimbille S U Dalm Source Type: research